Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07495202Phase 1Not Yet Recruiting

A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine

Role: lead

NCT06861101Phase 2Completed

Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults

Role: lead

NCT05242042Phase 2Terminated

JT001 (VV116) for the Early Treatment of COVID-19

Role: lead

All 3 trials loaded